The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
HOPA 2018 | Immunotherapy options for NSCLC: nivolumab, pembrolizumab or atezolizumab?
How do you decide on which drug to use when treating non-small cell lung cancer (NSCLC) patients in a second-line setting? Here, speaking at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO addresses the question of how to choose between nivolumab, pembrolizumab and atezolizumab for the treatment of NSCLC.
